|
1
|
In vivo effects of a GPR30 antagonist.
|
Nat Chem Biol
|
2009
|
2.39
|
|
2
|
Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity.
|
J Steroid Biochem Mol Biol
|
2011
|
1.42
|
|
3
|
Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30.
|
ACS Chem Biol
|
2007
|
1.37
|
|
4
|
Highly efficient synthesis and characterization of the GPR30-selective agonist G-1 and related tetrahydroquinoline analogs.
|
Org Biomol Chem
|
2010
|
0.94
|
|
5
|
Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers.
|
J Nucl Med
|
2008
|
0.86
|
|
6
|
Synthesis and characterization of tricarbonyl-Re/Tc(I) chelate probes targeting the G protein-coupled estrogen receptor GPER/GPR30.
|
PLoS One
|
2012
|
0.81
|
|
7
|
Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111in-labeled nonsteroidal imaging agents.
|
ACS Chem Biol
|
2010
|
0.81
|
|
8
|
Design and synthesis of a new class of membrane-permeable triazaborolopyridinium fluorescent probes.
|
J Am Chem Soc
|
2011
|
0.80
|
|
9
|
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
|
Bioorg Med Chem
|
2011
|
0.78
|
|
10
|
Erratum: G Protein-coupled Estrogen Receptor Protects from Atherosclerosis.
|
Sci Rep
|
2015
|
0.76
|